The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 study titled ‘A Phase 3 Randomized, ...

More women have Sjögren’s syndrome than breast cancer—90 percent of those that have it are women. The challenge is that only about one million are diagnosed.

Sjögren's Syndrome News CARRA 2025 Rituximab, Cyclophosphamide Combo Safe in Pediatric Patients Although the study was conducted at a single center, patients achieved clinical improvement and ...

Patients with Sjögren syndrome have an increased risk for non-Hodgkin lymphoma. It is estimated that approximately 10% of patients with significant dry eye disease have Sjögren syndrome.

Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome. JAMA, 2014; 312 (3): 249 DOI: 10.1001/jama.2014.7682 ...